CureVac N.V., a company based in Tübingen, Germany, needs less production capacity for CVnCOV, its mRNA vaccine candidate against Covid-19. As a result, it has terminated its contract with Wacker Chemie AG.
This will not have any significant impact on WACKER BIOSOLUTIONS' sales and earnings in 2021. 'And it does not change our medium-term targets for the Biosolutions division either,' said Dr. Susanne Leonhartsberger, the division's head. 'We are confident that we can provide other customers with the freed-up capacity for their mRNA and other molecules in the future,' added Dr. Susanne Leonhartsberger. WACKER's site in Amsterdam has manufactured vaccines for customers for more than 20 years.
Wacker Chemie AG
Corporate Communications
Joerg Hettmann
Send Message
Press Information
(PDF | 111 KB)
Attachments
- Original document
- Permalink
Disclaimer
Wacker Chemie AG published this content on 14 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 September 2021 05:21:02 UTC.